Skip to main content

Windtree Therapeutics Inc

WINT
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000946486

No open-market purchases or sales by Windtree Therapeutics Inc insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026
0
13F valueReported value at the end of Q2 2026
$0
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding WINT, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding WINT at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Windtree Therapeutics Inc insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 9, 2024 (view filing)Oct 81 dayFraser CraigPresident and CEOPPurchase+5.43K$0.91+$4.94K+169.3%8.64K after
Sep 28, 2023 (view filing)Sep 271 dayFraser CraigPresident and CEOPPurchase+2.50K$1.02+$2.55K+4.5%57.9K after
Sep 27, 2023 (view filing)Sep 261 dayFraser CraigPresident and CEOPPurchase+2.50K$0.90+$2.25K+4.7%55.4K after
Apr 27, 2023 (view filing)Apr 261 dayFraser CraigPresident and CEOPPurchase+1.50K$1.77+$2.65K+27.2%7.01K after
Apr 26, 2023 (view filing)Apr 251 dayFraser CraigPresident and CEOPPurchase+1.31K$1.89+$2.49K+31.3%5.51K after
Jul 27, 2022 (view filing)4:20 PM ETJul 27Same dayFraser CraigPresident and CEOPPurchase+2.50K$0.3799+$949.75+1.1%226.6K after
Jul 26, 2022 (view filing)4:38 PM ETJul 26Same dayHamill John P.SVP & CFOPPurchase+3.00K$0.3666+$1.10K+4.3%72.8K after
Jul 26, 2022 (view filing)4:37 PM ETJul 26Same dayFraser CraigPresident and CEOPPurchase+2.50K$0.374+$935+1.1%224.1K after
Jul 5, 2022 (view filing)4:40 PM ETJun 305 daysFraser CraigPresident and CEOPPurchase+4.50K$0.4279+$1.93K+2.1%221.6K after
Jun 30, 2022 (view filing)6:59 AM ETJun 291 dayFraser CraigPresident and CEOPPurchase+7.00K$0.4154+$2.91K+3.3%217.1K after

Top 10 13F holders, Q2 2026

The largest institutional positions in Windtree Therapeutics Inc at the end of Q2 2026; share changes are against Q1 2026.

View all: Top 10 13F holders, Q2 2026

No institution reported holding WINT in 13F filings for Q2 2026.